Evidence map›Paper›PMID 39108330›Full record

ArticleExploratory research in clinical and social pharmacy2024

Evaluation of viral suppression and medication-related burden among HIV-infected adults in a secondary care facility.

Erick Wesley Hedima, John David Ohieku, Emmanuel Agada David, Nasiru Yakubu Ikunaiye, Abdulrahman Nasir, Mustapha Ahmed Alfa, Safinat Abubakar, Ismaila Khalifas Bwiyam, Tang'an Zughumnaan Bitrus

Abstract read
In one paragraph

Article in Exploratory research in clinical and social pharmacy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Erick Wesley HedimaDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, Gombe State University, Nigeria.
John David OhiekuDepartment of Clinical Pharmacy and Pharmacy Administration, Faculty of Pharmacy, University of Maiduguri, Nigeria.
Emmanuel Agada DavidDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, Gombe State University, Nigeria.
Nasiru Yakubu IkunaiyeDepartment of Pharmaceutical Services, University of Maiduguri Teaching Hospital, Borno State, Nigeria.
Abdulrahman NasirDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, Gombe State University, Nigeria.
Mustapha Ahmed AlfaDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, Gombe State University, Nigeria.
Safinat AbubakarDepartment of Pharmaceutical Services, Specialists' Hospital, Gombe State, Nigeria.
Ismaila Khalifas BwiyamDepartment of Pharmaceutical Services, Specialists' Hospital, Gombe State, Nigeria.
Tang'an Zughumnaan BitrusDepartment of Pharmaceutical Services, Federal Teaching Hospital, Gombe State, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: People living with HIV/AIDS (PLHIV) are prone to other health issues that may result from the disease or antiretroviral medicines. These persons experience other psychosocial aspects of the illness, which may negatively affect their quality of life and overall treatment outcomes. This study assessed the medication-related burden and virological response of adult PLHIV. Method: This cross-sectional study involved 417 HIV-positive adults who had been on combined antiretroviral therapy for at least a year at the State Specialist Hospital Gombe. Nigeria. Patient medication experience was measured using the Living with Medication Questionnaire version-3 (LMQ-3). Virological suppression was assessed at viral loads <1000 copies/ml and 20 copies/ml for undetectable HIV RNA levels. The LMQ-3 scores were compared with the participants' characteristics using independent Results: Of the 417 PLHIV included in this study, 271 (65%) were classified as WHO Stage 1 ART initiation, 93.8% achieved viral suppression with 291 (69.5%) whom were females. The majority of patients 382 (91.6%) were on a dolutegravir-based regimen, had no tuberculosis diagnosis at antiretroviral therapy (ART) initiation (82.5%) and were 6-10 years on ART (46.3%). Only 67.6% of the population had a moderate medication-related burden. Female sex ( Conclusion: The findings from this study revealed that majority of the patients achieved viral suppression with moderate degree of medication-related burden. Targeted interventions should be directed toward younger patients, females and patients with unsuppressed viral loads.

Indexed as

Antiretroviral drugsHIVMedication-related burdenViral suppression

Identifiers

PMID39108330
PMCPMC11301334

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.